ELAVL1 and hepatocellular carcinoma: Preventing HCV induced cytoplasmic relocalization of HuR by either targeted PKC-δ inhibition or AMPK activation or by blocking the interaction of non-structural proteins with these kinases could offer novel therapeutic intervention against hepatocellular carcinoma progression.